Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine plus palonosetron versus dexamethasone plus palonosetron for chemotherapy-induced nausea and vomiting in gastrointestinal cancer
ChiCTR2200061017Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of olanzapine, palonosetron and dexamethasone in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Complete response rate (0-120 hours). Planned start Jun 2022; status: not yet recruiting.
02
Drugs
olanzapinepalonosetrondexamethasone
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR2200061017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061017.